1	Optimised methods for the targeted surveillance of extended-spectrum
2	beta-lactamase producing Escherichia coli in human stool
3	
4	Sarah Gallichan <sup>1</sup> , Sally Forrest <sup>1</sup> , Esther Picton-Barlow <sup>1</sup> , Claudia McKeown <sup>1</sup> ,
5	Maria Moore <sup>1</sup> , Eva Heinz <sup>1,2,</sup> Nicholas A Feasey <sup>1, 4</sup> , Joseph M Lewis <sup>1,3</sup> , Fabrice E
6	Graf <sup>1, *</sup>
7	
8	<sup>1</sup> Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool,
9	UK
10	<sup>2</sup> Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK
11	<sup>3</sup> Department of Clinical Infection, Microbiology & Immunology, University of Liverpool,
12	Liverpool, UK
13	<sup>4</sup> The School of Medicine, University of St Andrews, St Andrews, UK
14	
15	Keywords
16	Molecular epidemiology; Antimicrobial resistance; Transmission; Surveillance;
17	Microbiological methods; DNA extraction
18	
19	*Correspondence:
20	Fabrice Graf
21	Liverpool School of Tropical Medicine
22	Pembroke Place
23	Liverpool, UK

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 24 Abstract

Understanding transmission pathways of important opportunistic, drug resistant 25 26 pathogens, such as extended-spectrum beta-lactamase (ESBL) producing Escherichia coli, is essential to implementing targeted prevention strategies to 27 interrupt transmission and reduce the number of infections. To link transmission of 28 29 ESBL-producing *E. coli* (ESBL-EC) between two sources, single nucleotide resolution 30 of *E. coli* strains as well as *E. coli* diversity within and between samples is required. However, the microbiological methods to best track these pathogens are unclear. Here 31 32 we compared different steps in the microbiological workflow to determine the impact different pre-enrichment broths, pre-enrichment incubation times, selection in pre-33 enrichment, selective plating, and DNA extraction methods had on recovering ESBL-34 EC from human stool samples, with the aim to acquire high quality DNA for sequencing 35 and genomic epidemiology. We demonstrate that using a 4-hour pre-enrichment in 36 Buffered Peptone Water, plating on cefotaxime supplemented MacConkey agar and 37 extracting DNA using Lucigen MasterPure DNA Purification kit improves the recovery 38 of ESBL-EC from human stool and produced high-quality DNA for whole genome 39 sequencing. We conclude that our optimised workflow can be applied for single 40 nucleotide variant analysis of an ESBL-EC from stool. 41

## 42 Introduction

The spread of antimicrobial resistance (AMR) in bacterial pathogens is a global threat 43 to public health. Of particular concern are infections caused by extended-spectrum 44 beta-lactamase (ESBL) producing Escherichia coli, which is on the World Health 45 Organisations (WHO) priority AMR pathogen list<sup>1</sup>. ESBL-producing *E. coli* (ESBL-EC) 46 are resistant to aminopenicillins and 3rd-generation cephalosporin (3GC) antibiotics, 47 which are commonly used to treat infections caused by Gram-negative bacteria. 48 ESBL-EC infections can result in a higher mortality and longer hospital stays and may 49 require access to reserve antibiotics such as carbapenems<sup>2-4</sup>. 50

51


Infection prevention is preferable to cure and will concurrently reduce antibiotic use. 52 To prevent the acquisition of enteric pathogens in care facilities, it is critical to 53 understand their transmission pathways. This is challenging for near ubiquitous 54 organisms such as *E. coli*, which are frequently part of a healthy gut flora and can also 55 be opportunistic pathogens<sup>5</sup>. Typically, human faecal samples have been shown to 56 contain one to three different *E. coli* genotypes at any one time<sup>6</sup> although as many as 57 nine or more different *E. coli* genotypes per stool sample have been described<sup>7</sup>. The 58 number of multidrug resistant E. coli strains detected has also been shown to increase 59 with host age<sup>8</sup>. Therefore, differentiating intraspecies diversity of different *E. coli* 60 strains requires comparisons at single nucleotide variation (SNV) resolution<sup>9</sup>. To track 61 transmission events of ESBL-EC in care settings, microbiological methods need to 62 capture the within-host diversity of ESBL-EC within and between different samples 63 accurately and cost-effectively, even when present at low levels. Consensus on which 64 microbiological methods are optimal and a comprehensive comparison of the impact 65 of different microbiological methods are currently lacking. 66

67

Currently, the most common healthcare diagnostic method of ESBL-EC isolation from 68 69 human stool is direct plating on cefotaxime-supplemented MacConkey or chromogenic agar and confirming the production of ESBL using the double disk 70 diffusion method<sup>10,11</sup>. This is often followed by molecular investigation of ESBL 71 resistance genes via multiplex PCR<sup>12,13</sup>. While these methods are effective in 72 73 identifying the presence of an ESBL-EC to inform treatment options, they lack the resolution to infer transmission because they do not allow us to clearly distinguish 74 75 between closely related *E. coli*<sup>14</sup>. The distinction between two different clades within the same ST of *E. coli* can be as little as 70 nucleotides, therefore cannot be accurately 76 distinguished using PCR methods<sup>15</sup>. 77

78

Surveillance studies focused on describing transmission pathways pre-enrich samples 79 with low microbial load, i.e., from rectal swabs, to increase detection of present ESBL-80 EC<sup>16,17</sup>. Combined with whole-genome sequencing (WGS) this allows for accurate 81 clustering of isolates at SNV resolution. However, there is little consensus between 82 studies, or data on controlled comparisons, on the impact of pre-enrichment broth, 83 pre-enrichment duration, selective agar, and method of DNA extraction has on sample 84 diversity. Here, we describe an optimized approach for targeted surveillance of ESBL-85 EC from human stool samples at SNV resolution to inform transmission modelling with 86 the potential to capture within-host diversity. 87



**Figure 1** Graphical summary of the main research questions and comparisons preformed for each step of the microbiological

113

processing of ESBL-EC from stool

## 114 ESBL-EC growth dynamics in different pre-enrichment broths

Pre-enrichment broths (Brain-Heart Infusion, Tryptic Soy, Buffered Peptone Water and 115 Davis Minimal) commonly used in the recovery of ESBL-EC from clinical sources were 116 selected for comparison in this study. These pre-enrichment broths were prepared 117 according to the manufacturer's recommendations (Supplementary Table 1). We 118 used three reference strains encoding ESBLs: NCTC 13341 (bla<sub>CTX-M-15</sub>); NCTC 13476 119 120 (blaimp); NCTC 13846 (blactx-m-27), with the latter also encoding plasmid-derived colistin resistance (Supplementary Table 2). We further included a clinical isolate, 121 122 CAB17W, encoding blacTX-M-15 (Supplementary Table 2). The growth of single ESBL-EC isolates in different pre-enrichment broths was determined to establish growth 123 dynamics. Growth of the reference ESBL-EC (NCTC 13441) in four pre-enrichment 124 broths (BPW, DM, BHI, and TS) was monitored every 10 minutes through regular 125 optical density readings at 600 nm wavelength in the CLARIOstar plate reader (BMG 126 Labtech, Ottenberg, Germany) for 24 h. A population logistic model was fitted to the 127 resulting data with the Growthcurver package<sup>18</sup>. The recovery of *E. coli* from different 128 pre-enrichment broths with varying incubation times was tested. E. coli (NCTC 13441) 129 was inoculated (approximately 2 x 10<sup>7</sup> CFU/mL) into 5 mL of four pre-enrichment 130 broths (BPW, DM, BHI, and TS) and grown shaking at 37 °C and 220 rpm. After 2, 4, 131 6 and 8 hours, 1:10 serial dilutions of each pre-enrichment culture were performed 132 and dilutions 10<sup>-4</sup> to 10<sup>-12</sup> were spotted onto LB agar and incubated at 37°C overnight. 133 The following day, the number of colony forming units (CFUs) recovered from each 134 broth was calculated. 135

Stool was collected from three healthy volunteers, defined as individuals not using
antibiotics or experiencing any gastrointestinal problems. The stool was resuspended
in a stool diluent solution (1:5 w/v) prepared according to the maltodextrin-trehalose

method with the addition of 10% glycerol<sup>19</sup>. The stool slurry was mixed using a 139 magnetic stirrer for 15 minutes and allowed to sediment for 5 minutes. Supernatants 140 141 from each of the three stool slurries were mixed in equal proportions and stored in cryotubes at - 80 °C. Before use in experiments, the stool slurry was rapidly thawed in 142 a water bath at 37°C for 10 minutes and vortexed thoroughly. To determine the optimal 143 pre-enrichment broth and incubation time for the recovery of ESBL-EC from stool, a 144 spiked stool model was developed using 1 mL of the pooled stool slurry and a 1 µL 145 spike of the NCTC 13441 or CAB17W (approximately 1 x 10<sup>5</sup> CFU/mL). The ESBL-146 non-producing E. coli strain (NCTC 12241) was used as a negative control to 147 determine if the antibiotic supplement sufficiently inhibited growth. The spiked stool 148 models were pre-enriched using TS and BPW with and without the addition of 149 selection (1  $\mu$ g/mL cefotaxime) and incubated for 4 and 18 hours, shaking at 37 °C 150 and 220 rpm. Following incubation, 1:10 serial dilutions of each pre-enrichment culture 151 were made and dilutions (10<sup>-4</sup> to 10<sup>-7</sup> for the 4-hour incubation and 10<sup>-5</sup> to 10<sup>-8</sup> for the 152 18-hour incubation) were plated onto LB agar and CHROMagar in 10 µL spots and 153 incubated at 37 °C overnight. The number of CFUs recovered from each broth was 154 calculated. 155

156

# 157 **Recovery of ESBL-EC using different selective agars**

Selective agar (MacConkey, Membrane Lactose Glucoronide Agar (MLGA) and CHROMagar) commonly used in the recovery of ESBL-EC from environmental, clinical and food sources were selected for comparison in this study. These selective agars were prepared according to the manufacturer's recommendations (Supplementary Table 1). MacConkey and MLGA agars were supplemented to a final concentration of 1 µg/mL cefotaxime (Melford, Suffolk, UK). To assess the recovery of ESBL-EC from stool using selective agar, the stool spike model described above was used. The spiked stool was pre-enriched in BPW for 4 hours, shaking at 37°C and 220 rpm. Following incubation, 1:10 serial dilutions of each spiked stool sample were made, and  $10^{-4}$  to  $10^{-7}$  dilutions were plated onto MacConkey agar, CHROMagar and MLGA plates in 10 µL spots and incubated at 37 °C overnight. The number of CFUs recovered from each selective agar was calculated.

170

## 171 Limit of ESBL-EC detection with pre-enrichment compared with direct plating

A series of 100 µL of CAB17W ranging from 1 CFU/mL to 1 x 10<sup>8</sup> CFU/mL was spiked 172 into 100  $\mu$ L of stool slurry. The spiked stools were serially diluted (1:10) and 10  $\mu$ L of 173 each dilution was spotted onto cefotaxime supplemented MacConkey agar and 174 incubated at 37 °C overnight. A 96 deep well plate was then inoculated with 10 µL of 175 the remaining stool spikes in 1 mL of BPW, this was done in triplicate for each spike 176 input concentration. The deep well plate was then sealed with a breathable sealing 177 membrane and placed in an Innova 42R 19 mm Orbit shaking incubator set at 37 °C 178 and 220 rpm. After 4 hours the plate was removed from the incubator, each well was 179 again diluted in series 1:10 and spots of 10µL were plated onto cefotaxime 180 supplemented MacConkey and incubated at 37°C overnight. The number of CFUs 181 recovered were then calculated. 182

183

## 184 **DNA extraction kit comparison**

A single colony of each of four *E. coli* strains (**Supplementary Table 2:** NCTC 13441, NCTC 13476, NCTC 13846, CAB17W) were inoculated in 5 mL of LB with and grown overnight. Then, cultures were diluted to an OD600 of 2 ( $\sim 2 \times 10^9$  CFU/mL). The cells were washed three times in phosphate-buffered saline (PBS). The resulting pellets

were resuspended in 1 mL of PBS and split into three tubes with 250 µL and used as 189 the input for each extraction method. To assess the yield, guality, efficiency, and cost 190 of five commercially available kits (Supplementary Table 1) and a simple boiling 191 method<sup>20</sup>, we extracted DNA from each of the four *E. coli* isolates in technical 192 triplicates (n=12 for each extraction method), with three experimental replicates (n=36 193 extractions per method) on different days. The DNA yield was then measured using 194 195 the Qubit 4 Fluorometer (Agilent Technologies, California, USA) and the Agilent TapeStation System 4150 (Agilent Technologies, California, USA) was used to 196 197 determine the DNA integrity. The DNA quality was assessed by measuring the A260/230 and A260/280 absorbance ratios using the NanoPhotometer (Implen, 198 California, United States). Scores (Supplementary Table 3) were allocated according 199 to the criteria in **Supplementary Table 4**. Each DNA extraction method was then 200 ranked according to the score given, from highest (1) to lowest (6) preforming in each 201 category: DNA yield, DNA quality, cost, hands-on time, ease of protocol and total 202 protocol time. 203

204

## 205 Single nucleotide variant analysis

To determine whether our protocol would provide sufficient resolution for the detection 206 of single nucleotide variants in a stool sample, we processed a spiked stool sample 207 and an ESBL-EC positive rectal swab. For the spiked stool sample, we inoculated 10 208 μL of a 100-fold diluted overnight CAB17W culture (~ 8 x 10<sup>7</sup> CFU/mL) into 1 mL of 209 the pooled stool slurry, vortexed the mixture thoroughly and added 100  $\mu$ L to 5 mL of 210 BPW in a 15 mL Falcon tube. The ESBL-EC positive rectal swab was obtained with 211 permission from a participant in an observational cohort study of faecal ESBL carriage 212 in hospital patients and care home residents across Liverpool, UK. The rectal swab 213

was placed directly in 5 mL of BPW in a 15 mL Falcon tube. Falcon tubes were 214 incubated for 4 hours at 37 °C, shaking at 220 rpm. After 4 hours, 100 µL of the culture 215 was spread on cefotaxime supplemented (1 µg/mL) MacConkey agar and incubated 216 at 37 °C overnight. The following day, we picked 7 single colonies, restreaked each 217 colony on another cefotaxime supplemented MacConkey agar and incubated at 37 °C 218 overnight. DNA was then extracted from each of the purified colonies using the 219 MasterPure Complete DNA and RNA Purification Kit (Lucigen, Wisconsin, USA) 220 221 according to the manufacturer's recommendations. The DNA concentrations were then measured using the Qubit 4 Fluorometer (Agilent Technologies, California, USA) 222 and the DNA sent for whole-genome sequencing using the NovaSeq platform (Illumina 223 Inc, California, USA) at Azenta Life Sciences (Frankfurt, Germany). Sequence data 224 (reads) were obtained as fastq files. Sequencing adaptors were removed from the 225 reads using Trimmomatic version 0.39<sup>21</sup> and the quality of the trimmed reads was 226 assessed using the quality metrics provided by FastQC version 0.11.9<sup>22</sup>. ARIBA<sup>23</sup> was 227 used to call the AMR genes using the CARD database<sup>24</sup> and to determine ESBL-EC 228 multilocus sequence type as defined by the seven-gene Achtman scheme<sup>25</sup> hosted at 229 pubMLST (https://pubmlst.org/). Single nucleotide variants (SNVs) were called 230 between the relevant reference genome (ST167: GCF 025398915.1; ST131: 231 GCF\_004358405.1; ST1193: GCF\_003344465.1) and the single pick sequences 232 using snippy version 4.3.6 (https://github.com/tseemann/snippy). We then generated 233 a core genome alignment of all the single pick sequences using snippy-core (with 234 default settings). All non-nucleotide characters and potentially recombinant sequence 235 regions were removed from the multisequence alignment using the snippy-236 clean\_full\_aln and Gubbins version 2.3.4<sup>26</sup> respectively. We then extracted the SNVs 237 from the cleaned multisequence alignment using snp-sites (using the -c option) and 238

created a pairwise SNV distance comparison between each single pick sequence
using snp-dists version 0.8.2 (https://github.com/tseemann/snp-dists).

241

## 242 Statistical analysis

Measurements were summarised as mean and standard deviation or 95% confidence 243 interval, calculated as one standard deviation above and below the mean value. Box-244 245 and-whisker plots, where presented, show medians as a horizontal line, 25th and 75th centiles as boxes, and at most 1.5 times interguartile range as whiskers. Analysis of 246 247 variance (ANOVA) tests were used to determine the significance of any observed differences between groups. P < 0.05 was considered statistically significant and, 248 where appropriate, P values were adjusted for multiple comparisons using the 249 Bonferroni correction. A post-hoc Tukey test was used for pairwise sample 250 comparisons when ANOVA tests were significant. All statistical analysis was 251 performed using R version 4.1.3<sup>27</sup>. All R code is accessible from our Github repository 252 (https://github.com/SarahGallichan/ESBL-EC methods.git) 253

254

255 **Results** 

ESBL-EC recovery using different pre-enrichment conditions and selective
 agars


We assessed the growth dynamics of two ESBL-EC strains (NCTC 13441 and CAB17W) in different pre-enrichment broths to determine the optimal incubation time for recovery of bacteria in log growth phase (**Supplementary Figure 1**). To summarise the dynamics of the resulting growth curves, the data was fitted to a population logistic model (**Supplementary Table 5**). ESBL-EC reached midpoint of log-phase after approximately 4 hours in BHI, TS, and DM; and after approximately 7 hours in BPW.


Therefore, we chose incubation times of between 2 and 8 hours to quantify ESBL-EC 264 recovery from different broths and assessed bacterial count in CFU from each broth 265 after 4 incubation time points (2, 4, 6 and 8 hours). Across all 4 time points, BHI 266 resulted in the highest and DM the lowest *E. coli* recovery (Supplementary Figure 2). 267 We performed pair-wise broth comparisons at each time point. There was no 268 significant difference between E. coli growth in BHI, BPW and TS across all 4 time 269 270 points (Supplementary Table 6). However, *E. coli* counts in DM was significantly lower than BHI and BPW after 2 hours; BHI, BPW and TS after 4 hours; and BHI and 271 272 TS after 8 hours of incubation. The largest increase in amount of E. coli CFU recovered between the two time points for each broth was from 2 to 4 hours of incubation 273 (Supplementary Table 6), which is within the log growth phase of *E. coli* in each broth. 274 Therefore, we selected 4 hours of incubation to investigate the growth of ESBL-EC 275 from spiked stool. 276

277

We selected TS (a high nutrient broth with multiple amino acid sources) and BPW (a 278 low nutrient broth with one amino acid source) for the spike experiments, adding 279 defined amounts of ESBL-EC (NCTC 13441 and CAB17W) to stool samples. Donated 280 stool was confirmed to have no growth of cefotaxime (a 3GC) resistant bacteria by 281 plating on 1µg/mL cefotaxime supplemented MacConkey. We assessed the recovery 282 of these spiked strains, testing whether the addition of selection with cefotaxime and 283 the length of incubation time influenced the concentration of spiked ESBL-EC strains 284 we were able to recover (Figure 2). After 4 hours of incubation, there was no 285 significant difference in CAB17W growth (i.e. CFU concentration) between TS and 286 BPW and whether antibiotic was supplemented or not. However, at 4 hours the growth 287 of NCTC 13441 in the TS without antibiotic supplement was 2.75 CFU/mL (CI: 2.28 -288

- 3.33, p = 0.0004) more than in BPW without supplement, while there was no significant
- 290 difference between the growth in either broth at 4 hours when supplemented with
- 291 cefotaxime.





*Figure 2* Growth of reference (NCTC 13441) and clinical (CAB17W) ESBL-EC spiked into human stool under different pre-enrichment conditions. The spiked stool models were pre-enriched in different broths (Buffered Peptone Water and Tryptic Soy) for incubation times (4-hour and 18-hour), with and without the addition of the antibiotic cefotaxime.

292

At 18 hours the effects of the addition of cefotaxime and broth on growth were different for each strain. Antibiotic supplement significantly increased the recovery of NCTC

13441 after 18 hours compared to no supplementation in TS, by 100.78 CFU/mL (CI: 295 39.81 - 251.19, p = 0.01). There was no significant difference in growth of NCTC 296 13441 at 18 hours between TS and BPW. However, recovery of CAB17W was 297 significantly higher in BPW after 18 hours of incubation compared to TS, by a 298 difference of 68 CFU/mL (CI: 51.11 - 91.26, p = 0.0001) with antibiotic supplement 299 and 41.16 CFU/mL (CI: 33.15 - 51.10, p < 0.0001) without an antibiotic supplement. 300 301 While an 18-hour pre-enrichment in antibiotic supplemented broth best recovered the highest CFU/mL for both NCTC 13441 and CAB17W, there were inconsistencies 302 303 between broths depending on the strain. Therefore, we concluded that a 4-hour preenrichment in BPW was better for a more consistent increase in both ESBL-EC strains 304 without requiring an antibiotic supplement. 305


Next, we then compared ESBL-EC recovery on three different ESBL-EC selective agars (CHROMagar, MLGA and MacConkey) from our stool spike models. ESBL-EC was recovered from all agars, with no significant differences in CFU/mL (**Supplementary Table 8**). However, there was a clear difference in the cost per sample of each selective agar, with MacConkey being the most cost-effective and CHROMagar being the most expensive (**Supplementary Table 1**).

312

The limit of ESBL-EC detection from CAB17W spiked stool was then determined for 4-hour pre-enrichment in BPW and compared with directly plating on cefotaxime supplemented MacConkey. Overall, the mean difference in ESBL-EC recovery between 4-hour pre-enrichment in BPW and direct plating was 47 CFU/mL (CI: 9.65 - 233.08, p < 0.001) (Supplementary Figure 3). The limit of detection using direct plating was 1.91 CFU/mL and with a 4-hour pre-enrichment, the limit of detection improved to 0.05 CFU/mL.

320	

Large variability in yield and quality of DNA using different extraction methods 321 DNA from the same input concentration of four different E. coli strains 322 (Supplementary Table 2) was extracted using five commercially available kits (Table 323 3) and a simple boiling method. The DNA yield was measured using the Qubit 324 fluorometer (Figure 3). The boiling method resulted in the highest mean DNA yield 325 326 overall for the Qubit (16.66 ng/mL, 95% CI: 16.16 - 17.16) while the DNeasy kit resulted in the lowest (3.28 ng/mL; 95% CI: 4.28 – 2.28) (Figure 3). 327



Extraction Kit

Figure 3 DNA yield from the six extraction methods measured using the Qubit. Technical (each sample extracted in triplicates) and experimental replicates (each extraction method performed three separate times) are plotted for each extraction kit (n = 36). The outliers are shown as points outside of the boxplot whiskers.

328

329 The DNA quality was assessed using the A260/280 absorbance ratio. Downstream applications requiring high quality DNA, such as short-read and especially long-read 330 sequencing platforms, require that the A260/A280 absorbance ratio is in the range 331

between 1.8 to 2.1. The Promega Wizard kit and the DNeasy kit had the largest 332 proportion of technical and experimental replicates (67%) within this range while the 333 Zymo Miniprep kit had the lowest proportion (11%) (Figure 4A). Additionally, the DNA 334 integrity was assessed with the DNA Integrity Number (DIN), which is a numerical 335 assessment (1 to 10) of the DNA integrity determined by the TapeStation system 336 algorithm. A DIN score of 1 indicated very degraded DNA and DIN 10 indicated highly 337 338 intact DNA. The Lucigen MasterPure and the Zymo miniprep kits had the highest DIN followed closely by the Promega Wizard (Table 1). 339

340


Table 1 Mean of measurements (technical and experimental replicates averaged
 across three independent experiments) for each DNA extraction method, including
 the 95% confidence intervals, for the tested E. coli and proportion (percentage of
 technical replicates) within defined absorbance ratio range.

345						
	Boiling	DNeasy	Lucigen	Promega	NEB	Zymo
			MasterPure	Wizard	Monarch	Miniprep
DNA yield	10.00 1.00		40.07 0.70	/		
(ng/ μL)	16.66 ± 4.66	3.28 ± 1.00	13.37 ± 0.58	7.37 ± 1.62	7.35 ± 0.97	4.85 ± 0.48
Absorbance ratio		4 00 0 45	0.4 0.00	0.00 0.40	4.74 0.45	4 00 0 47
(A260/A280)	1.74 ± 0.06	$1.99 \pm 0.15$	2.1 ± 0.03	$2.06 \pm 0.13$	1.74 ± 0.15	1.66 ± 0.17
Proportion within	4.407	070/	500/	070/	100/	4.404
range (1.8 – 2.1)	14%	67%	50%	67%	42%	11%
Absorbance ratio	$0.70 \pm 0.04$		$3  2.89 \pm 0.60  4.44 \pm 1.27  1.2 \pm 0.63$			
(A260/A230)		$3.00 \pm 0.73$		$1.2 \pm 0.63$	1.74 ± 0.41	
Proportion within		50%	59%	0%	8%	0%
range (2.0 – 3.0)	0%					
DNA Integrity		<b>F</b> 40 0 <b>F</b> 0	7 40 0 05	740 047	0.00 0.47	7 40 0 67
Number	1.97 ± 1.56	$5.40 \pm 0.50$	7.40 ± 0.35	7.18 ± 0.45	6.08 ± 0.45	7.40 ± 0.25

346

The purity of extracted DNA was assessed using the 260/230 absorbance ratio. DNA with a 260/230 absorbance ratio of 2.0 - 3.0 are considered pure and mostly free of contaminants (such as phenols) <sup>28</sup>. Lucigen Masterpure had the largest proportion of

- replicates (59%) within the suggested A260/A230 absorbance range, while the simple
- boiling method, the Zymo miniprep kit and the Promega Wizard kit failed to yield DNA
- within this purity range (Figure 4B).



**Figure 4** Absorbance ratios **(A)** A260/280 and **(B)** A260/230 indicating the presence of contamination and quality of DNA, respectively, of the extracted DNA extracted using six extraction methods. Technical (each sample extracted in

triplicates) and experimental replicates (each extraction method preformed three separate times) are plotted for each extraction kit (n = 36). The outliers are shown as points outside of the boxplot whiskers.

Using all the measurement data, cost, ease of protocol (technical difficulty and 353 equipment requirements), and time aspects (hands-on and total-protocol time) from 354 the comparison of the five commercially available DNA extraction kits, a ranking matrix 355 (Table 2) was produced based on the scores for each extraction method 356 (Supplementary Table 3). Simple boiling scored highly for yield, cost, and time but 357 358 low for the purity scores (A260/230, A260/280 and DIN). Commercial kits performed better in this regard, with the Promega HMW and Qiagen DNeasy ranking highest for 359 the A260/280 and the MasterPure ranking highest for the A260/230 absorbance ratio 360 and the DIN score. All other rankings were variable between kits. The Lucigen 361 MasterPure Complete DNA and RNA Purification Kit performed best for the extraction 362 of high yield and quality DNA for sequencing to investigate single nucleotide variants 363 of ESBL-EC in stool. 364

 Table 2 Ranking of different DNA extraction methods, highest (1) to lowest (6).

		Time	e			
DNA extraction kit	Cost	Hands-on	Total	Mean DNA yield (ng/ μL)	DNA quality	Difficulty
Qiagen DNeasy	5	2	3	2	5	3
Lucigen Masterpure	2	4	5	1	1	6
Promega HMW	5	4	5	2	1	5
NEB Monarch	3	1	2	2	4	2
Zymo Miniprep	4	2	3	2	1	3
Boiling	1	1	1	1	6	1

## 370 Validation of workflow

To investigate whether our workflow of a 4-hour pre-enrichment in BPW, plating on 371 cefotaxime supplemented MacConkey and extraction using the MasterPure kit was 372 sufficient for investigation of SNVs in closely related ESBL-EC strains, we performed 373 both a control experiment where we processed an ESBL-negative stool spiked with a 374 single clinical ESBL-EC strain (CAB17W) and assessed an ESBL-EC positive patient 375 376 rectal swab using our workflow. Seven colonies from each of the cefotaxime supplemented MacConkey agar plates were then picked and sequenced. SNV 377 378 analysis of the spiked stool confirmed that there were no SNVs between any of the single colony pick genomes as expected for a clonal spike (Supplementary Table 379 **10)**. Analysis of the ESBL-EC positive rectal swab revealed that the patient had two 380 different ESBL-EC sequence types ST131 that had blacTX-M-27 and ST1193 that had 381 blactx-M-15. SNV analysis of each ESBL-EC sequence type showed that there were 5 382 SNV differences between the ST131 single picks (Supplementary Table 11) and 1 383 SNV difference between one of the ST1193 picks and the other four single picks 384 (Supplementary Table 12). We therefore concluded that our workflow was 385 appropriate for SNV analysis of ESBL-EC from stool. 386

387

#### 388 Discussion

Although *E. coli* is the dominating species of Enterobacteriaceae in the gut of healthy human adults, *E. coli* only constitute around 0.5% - 5% of the gut microbial community <sup>29</sup>. This makes it difficult for methods such as shotgun metagenomics to disentangle the diversity of pathogenic and non-pathogenic *E. coli* within a highly complex human gut microbiome without using costly very deep sequencing <sup>6,30</sup>. On the other end of the spectrum, the analysis of single colony picks from stool samples directly plated on

antibiotic supplemented agar, as is practice in many routine diagnostic laboratories, is 395 insufficient to capture the intraspecies diversity of ESBL-EC, which can be substantial, 396 as each colony would need to be analysed which would be extremely time-, cost- and 397 labour-intensive<sup>31,32</sup>. Both methods are thus not feasible to implement as routine tool 398 to monitor transmission of ESBL-EC in healthcare settings. Therefore, we investigated 399 the impact of different microbiological approaches to optimise the recovery of ESBL-400 401 EC from human stool. We compared different methods at each stage of laboratory processing; pre-enrichment, isolation on selective agar, and DNA extraction, and were 402 403 able to optimise a rapid and cost-effective approach for the recovery of ESBL-EC for targeted surveillance of ESBL-EC colonisation with the potential for sub-species 404 resolution. 405

406

Numerous transmission studies have highlighted the challenge of capturing ESBL-EC 407 variants present in small numbers in stool<sup>33-35</sup>. E. coli are only a small part of the 408 diversity present within complex matrices and clinical samples (e.g., stool), increasing 409 the likelihood of a test resulting in false negatives when stool is directly plated on 410 supplemented agar<sup>36,37</sup>. To improve ESBL-EC detection for targeted surveillance, 411 previous studies used pre-enrichment broth before plating on supplemented agar and 412 were successful in recovering multiple ESBL-EC genotypes from human stool<sup>17</sup>. 413 Indeed, we also showed that pre-enrichment is an effective tool to increase sensitivity 414 for ESBL-EC detection from stool, thus improving the amount of ESBL-EC recovered 415 on supplemented agar. 416

417

The standard practice of pre-enriching a sample for 18 to 24 hours is not conducive to rapid diagnosis and patient intervention<sup>38,39</sup>. A further concern with longer pre-

enrichment is the increased risk of creating competition with other lineages or species 420 and skewing the relative abundance. Further, the potential of movement of mobile 421 genetic elements (e.g. plasmids) can bias the recovery of the original strain<sup>40</sup>. We 422 found that growth of ESBL-EC was variable and strain-dependent after an 18-hour 423 pre-enrichment with and without the addition of an antibiotic supplement, suggesting 424 that there is indeed potential for competition bias with longer incubation times. 425 426 Therefore, we investigated a short pre-enrichment and found that a 4-hour preenrichment yielded sufficient growth for reliable downstream identification of ESBL-427 428 EC. Hence, we concluded that 4-hour pre-enrichment was not only preferable for consistent ESBL-EC recovery but also did not necessitate the addition of an antibiotic 429 supplement and reduced the time and cost. 430

431

There are a variety of recommended supplemented agars available for ESBL-EC 432 detection. Cefotaxime supplemented MacConkey agar is commonly used for 433 surveillance studies and clinical microbiology laboratories since it is readily available 434 and the cheapest of the three agars compared here<sup>10,11,41</sup>. However, chromogenic 435 agar (CHROMagar ESBL<sup>42</sup>) is an increasingly popular alternative to MacConkey since 436 it is effective at distinguishing between E. coli and other ESBL-producing 437 Enterobacteriaceae using colour<sup>38,43,44</sup>. In addition to these two agars, we also tested 438 ESBL-EC recovery on cefotaxime supplemented Membrane Lactose Glucuronide 439 Agar (MLGA), which is commonly used for detecting faecal contamination in water 440 sources<sup>45</sup>. We found that all three agars were effective in recovering from ESBL-EC 441 from pre-enriched stool, allowing for flexibility with selective agar choice; we hence 442 selected cefotaxime supplemented MacConkey as the most cost-effective in our 443 setting. 444

445

We tested a wide variety of DNA extraction methods including commercial DNA 446 purification kits and the boiling method as the simplest and cheapest method of DNA 447 extraction from *E. coli*<sup>46</sup>. Since transmission studies require high resolution typing to 448 clearly distinguish between two E. coli strains, high quality DNA is required. 449 Commercially available kits provide standardised reagents, consumables and 450 451 validated DNA extraction and purification methods. Depending on the extraction protocol, specialised equipment e.g. refrigerated centrifuges, skilled personnel, and 452 453 an increased amount of time and cost are needed to extract DNA<sup>47</sup>. Taking this into consideration, along with the cost-per-sample, quality, and yield of DNA we compared 454 six DNA extraction methods. While the boiling method was the simplest, cheapest, 455 least time-consuming DNA extraction method with the highest yield and thus arguably 456 of high value for highly time-sensitive applications or in cost-restricted setting, we show 457 that the Lucigen MasterPure produced comparable DNA yield with much higher quality 458 scores that were consistently reproducible. 459

460

Finally, we validated our optimised ESBL-EC recovery method using a spiked stool 461 sample and a patient rectal swab. For the spiked stool sample, all sequenced 7 462 colonies were identical and clonality was confirmed at single nucleotide resolution. 463 With the patient rectal swab, we demonstrated the value of multiple colony picks 464 through the recovery of two different ESBL-EC sequence types and the analysis of 465 variation within each sequence type at single nucleotide resolution. The analysis of 466 both samples at suggests that our method is suitable for studies aiming to infer 467 transmission using SNV. While the methods we show here have focused on the 468 recovery of ESBL-EC from stool, we suggest that these methods are also applicable 469

or easily adaptable for the recovery other drug resistant Enterobacteriaceae. ESBLproducing *Klebsiella* and *Enterobacter* species occupy a similar niche to ESBL-EC and are all recovered from stool through direct plating on supplemented agar<sup>10</sup>. With the increasing prevalence of drug resistant infections worldwide, it has become crucial to understand transmission pathways to put targeted preventative measures in place to interrupt transmission.

476

Our study demonstrates that a 4-hour pre-enrichment in either BPW or TS is effective 477 478 for the recovery of ESBL-EC from stool without the addition of a third-generation cephalosporin and cefotaxime supplemented MacConkey, chromogenic agar and 479 MLGA are all viable options for the recovery of pre-enriched ESBL-EC. The quality 480 and quantity of DNA using different extraction kits is variable and not all yield high-481 quality DNA required for whole genome sequencing. The MasterPure Complete DNA 482 and RNA Purification Kit produced a DNA yield that was comparable to the simple 483 boiling method, but with higher quality scores that were consistently reproducible. 484 Altogether this optimised workflow performs well for SNV analysis of ESBL-EC from 485 stool and can thus be applied for genomic epidemiology and transmission studies. 486

487

#### 488 Ethics

The healthy volunteers gave confidential consent for the use and storage of stool samples (LSTM Research Tissue Bank RTB/2022/007). The observational cohort study of hospital patients and care home residents in facilities in Liverpool was approved by the National Research Ethics Service Greater Manchester South ethics committee (ref: 22/NW/0343). Written informed consent was obtained from participants or consultees, as appropriate.

#### 495

519

## Supplementary materials and data availability 496 Supplementary Tables 1 – 12 and Supplementary Figures 1 - 3 are accessible in the 497 supplementary material of this manuscript. The R scripts used to generate the figures, 498 supplementary figures and data analyses in this manuscript are available from the 499 GitHub https://github.com/SarahGallichan/ESBL-EC methods.git. 500 repository 501 Protocols are available on Protocols.io (dx.doi.org/10.17504/protocols.io.kxygxyk3dl8j/v). Reads from sequenced isolates in 502 this study are accessible in the Sequence Read Archive (SRA) using BioProject ID: 503 PRJNA1095376. 504 505 Funding 506 This work was supported by iiCON (infection innovation consortium) via UK Research 507 and Innovation (107136) and Unilever (MA-2021-00523N). 508 509 Author contributions 510 Conceptualisation and method development was done by S.G., S.F., M.M., E.H., 511 J.M.L., N.A.F., and F.E.G. Investigation was undertaken by S.G., S.F., E.P.-B, and 512 C.M. Data analysis was done by S.G., J.M.L. and F.E.G. The original draft was 513 prepared by S.G., E.H., J.M.L., N.A.F., and F.E.G and then reviewed and edited by all 514 authors. Supervision was provided by E.H., J.M.L., N.A.F., and F.E.G. 515 516 **Acknowledgements** 517 We would like to thank Ross Gray for the illustrations used in Figure 1 of this 518 manuscript, Finlay Hitchman for his assistance with the pre-enrichment broth

520 comparison work, and all the clinical staff and study participants that facilitated this

521 study.

#### 522 **References**

- 523 1. WHO publishes list of bacteria for which new antibiotics are urgently needed.
- 524 https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-
- 525 which-new-antibiotics-are-urgently-needed.
- 526 2. Schwaber, M. J. & Carmeli, Y. Mortality and delay in effective therapy associated
- with extended-spectrum beta-lactamase production in Enterobacteriaceae
  bacteraemia: a systematic review and meta-analysis. *J Antimicrob Chemother*
- **60**, 913–920 (2007).
- Melzer, M. & Petersen, I. Mortality following bacteraemic infection caused by
   extended spectrum beta-lactamase (ESBL) producing E. coli compared to non ESBL producing E. coli. *Journal of Infection* 55, 254–259 (2007).
- Blom, A., Ahl, J., Månsson, F., Resman, F. & Tham, J. The prevalence of ESBLproducing Enterobacteriaceae in a nursing home setting compared with elderly
  living at home: a cross-sectional comparison. (2016) doi:10.1186/s12879-0161430-5.
- 537 5. Bettelheim, K. A. Escherichia coli in the normal flora of humans and animals. in 538 *Escherichia coli: mechanisms of virulence* (ed. Sussman, M.) 85–109 539 (Cambridge University Press, Cambridge, 1997).
- Foster-Nyarko, E. & Pallen, M. J. The microbial ecology of Escherichia coli in
  the vertebrate gut. *FEMS Microbiol Rev* 46, (2022).
- Alm, E. A., W. S. T., and G. D. M. The niche of Escherichia coli. in *In Population Genetics of Bacteria: A Tribute to Thomas S. Whittam* (eds. Walk, S. T. & Feng,
- 544 P. C. H.) 68–89 (ASM Press, Washington, DC, USA, 2011).

- Vollmerhausen, T. L. *et al.* Population structure and uropathogenic virulence
   associated genes of faecal Escherichia coli from healthy young and elderly
   adults. *J Med Microbiol* **60**, 574–581 (2011).
- 548 9. Balloux, F. *et al.* From Theory to Practice: Translating Whole-Genome 549 Sequencing (WGS) into the Clinic. *Trends Microbiol* **26**, 1035–1048 (2018).
- 10. Public Health England. UK Standards for Microbiology Investigations Detection
- 551of EnterobacteriaceaeProducingExtendedSpectrumβ-Lactamases-552Standards-for-Microbiology-Investigations-Smi-Quality-and-Consistency-in-
- 553 *Clinical-Laboratories*. (2016).
- 11. World Health Organization & Advisory Group on Integrated Surveillance on
- 555 AMR. WHO Integrated Global Surveillance on ESBL-Producing E. Coli Using a
- 556 *"One Health" Approach: Implementation and Opportunities.* 557 https://www.who.int/publications/i/item/9789240021402 (2021).
- Bradford, P. A. Extended-spectrum beta-lactamases in the 21st century:
  characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev* 14, 933–951 (2001).
- 13. Naas, T., Cotellon, G., Ergani, A. & Nordmann, P. Real-time PCR for detection
  of blaOXA-48 genes from stools. *J Antimicrob Chemother* 68, 101–104 (2013).
- 563 14. Wu, G. *et al.* Comparative Analysis of ESBL-Positive Escherichia coli Isolates
  564 from Animals and Humans from the UK, The Netherlands and Germany. *PLoS*565 *One* 8, e75392 (2013).
- 15. Petty, N. K. *et al.* Global dissemination of a multidrug resistant Escherichia coli
  clone. *Proc Natl Acad Sci U S A* **111**, 5694–5699 (2014).

568	16.	Toombs-Ruane, L. J. et al. Carriage of Extended-Spectrum-Beta-Lactamase-
569		and AmpC Beta-Lactamase-Producing Escherichia coli Strains from Humans
570		and Pets in the Same Households. Appl Environ Microbiol 86, (2020).
571	17.	Ludden, C. et al. Defining nosocomial transmission of Escherichia coli and
572		antimicrobial resistance genes: a genomic surveillance study. Lancet Microbe
573		<b>2</b> , e472–e480 (2021).
574	18.	Sprouffske, K. & Wagner, A. Growthcurver: An R package for obtaining
575		interpretable metrics from microbial growth curves. BMC Bioinformatics 17, 1-4
576		(2016).
577	19.	Burz, S. D. et al. A Guide for Ex Vivo Handling and Storage of Stool Samples
578		Intended for Fecal Microbiota Transplantation. Sci Rep 9, (2019).
579	20.	Dashti, A. A., Jadaon, M. M., Abdulsamad, A. M. & Dashti, H. M. Heat Treatment
580		of Bacteria: A Simple Method of DNA Extraction for Molecular Techniques.
581		<i>Kuwait Medical Journal</i> <b>41</b> , 117–122 (2009).
582	21.	Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for
583		Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
584	22.	Andrews, S. FastQC: A Quality Control tool for High Throughput Sequence
585		Data. https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (2010).
586	23.	Hunt, M. et al. ARIBA: rapid antimicrobial resistance genotyping directly from
587		sequencing reads. Microb Genom 3, (2017).
588	24.	Alcock, B. P. et al. CARD 2023: expanded curation, support for machine
589		learning, and resistome prediction at the Comprehensive Antibiotic Resistance
590		Database. Nucleic Acids Res 51, D690–D699 (2023).
591	25.	Wirth, T. et al. Sex and virulence in Escherichia coli: an evolutionary perspective.
592		<i>Mol Microbiol</i> <b>60</b> , 1136–1151 (2006).

593	26.	Croucher, N. J. et al. Rapid phylogenetic analysis of large samples of
594		recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids
595		<i>Res</i> <b>43</b> , e15–e15 (2015).
596	27.	R Core TeamR: A Language and Environment for Statistical Computing R
597		Foundation for Statistical Computing, Vienna, Austria. <https: td="" www.r-<=""></https:>
598		project.org/> (2023).
599	28.	DNA Purification   DNA Extraction Methods   Promega.
600		https://www.promega.co.uk/resources/guides/nucleic-acid-analysis/dna-
601		purification/.
602	29.	Tenaillon, O., Skurnik, D., Picard, B. & Denamur, E. The population genetics of
603		commensal Escherichia coli. Nat Rev Microbiol 8, 207–217 (2010).
604	30.	Huttenhower, C. et al. Structure, function and diversity of the healthy human
605		microbiome. Nature 2012 486:7402 486, 207–214 (2012).
606	31.	Stoesser, N. et al. Extensive Within-Host Diversity in Fecally Carried Extended-
607		Spectrum-Beta-Lactamase-Producing Escherichia coli Isolates: Implications for
608		Transmission Analyses. J Clin Microbiol 53, 2122–2131 (2015).
609	32.	Pallen, M. J. et al. Genomic diversity of Escherichia coli from healthy children in
610		rural Gambia. doi:10.7717/peerj.10572.
611	33.	Aguilar-Bultet, L. et al. Within-host genetic diversity of extended-spectrum beta-
612		lactamase-producing Enterobacterales in long-term colonized patients. Nature
613		Communications 2023 14:1 <b>14</b> , 1–14 (2023).
614	34.	Adler, A. et al. Transmission dynamics of ESBL-producing Escherichia coli
615		clones in rehabilitation wards at a tertiary care centre. Clinical Microbiology and
616		Infection 18, E497–E505 (2012).

35. Duval, A. *et al.* Close proximity interactions support transmission of ESBL-K.

- pneumoniae but not ESBL-E. coli in healthcare settings. *PLoS Comput Biol* 15,
  e1006496 (2019).
- 36. Peto, L. *et al.* Selective culture enrichment and sequencing of feces to enhance
   detection of antimicrobial resistance genes in third-generation cephalosporin
   resistant Enterobacteriaceae. *PLoS One* 14, (2019).
- 623 37. Huttenhower, C. *et al.* Structure, function and diversity of the healthy human 624 microbiome. *Nature* **486**, 207–214 (2012).
- 38. Rondinaud, E., Ruppé, E., Matheron, S., Lucet, J. C. & Armand-Lefevre, L.
  Screening methods for intestinal carriage of multidrug-resistant
  Enterobacterales: interest of enrichment broth. *Diagn Microbiol Infect Dis* 97,
  115079 (2020).
- 39. Jazmati, T., Hamprecht, A. & Jazmati, N. Comparison of stool samples and
  rectal swabs with and without pre-enrichment for the detection of thirdgeneration cephalosporin-resistant Enterobacterales (3GCREB).
  doi:10.1007/s10096-021-04250-1/Published.
- 40. Conrad, C. C., Stanford, K., McAllister, T. A., Thomas, J. & Reuter, T.
  Competition during enrichment of pathogenic Escherichia coli may result in
  culture bias. *https://doi.org/10.1139/facets-2016-0007* 1, 114–126 (2016).
- 41. Jacob, M. E., Keelara, S., Aidara-Kane, A., Matheu Alvarez, J. R. & FedorkaCray, P. J. Optimizing a Screening Protocol for Potential Extended-Spectrum βLactamase Escherichia coli on MacConkey Agar for Use in a Global
  Surveillance Program. *J Clin Microbiol* 58, (2020).
- 64042.CHROMagar™ESBL-Chromagar.641https://www.chromagar.com/en/product/chromagar-esbl/.

642	43.	El-Jade, M. R. et al. ESBL Detection: Comparison of a Commercially Available
643		Chromogenic Test for Third Generation Cephalosporine Resistance and
644		Automated Susceptibility Testing in Enterobactericeae. PLoS One 11,
645		e0160203 (2016).

- 646 44. Réglier-Poupet, H. *et al.* Performance of chromID ESBL, a chromogenic medium
  647 for detection of Enterobacteriaceae producing extended-spectrum β648 lactamases. *J Med Microbiol* 57, 310–315 (2008).
- 45. Sartory, D. P. & Howard, L. A medium detecting β-glucuronidase for the
  simultaneous membrane filtration enumeration of Escherichia coli and coliforms
  from drinking water. *Lett Appl Microbiol* **15**, 273–276 (1992).
- 46. Shah DH, S. S. B. T. C. D. *Molecular Detection of Food Borne Pathogens*.
  (Taylor & Francis Group, CRC Press, USA, 2010).
- 47. Barbosa, C., Nogueira, S., Gadanho, M. & Chaves, S. DNA extraction: finding
  the most suitable method. *Molecular Microbial Diagnostic Methods: Pathways to Implementation for the Food and Water Industries* 135–154 (2016)
- 657 doi:10.1016/B978-0-12-416999-9.00007-1.